Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff P Sharman

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Haematologica|December 17, 2020
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO studyAnthony R Mato, Jeff P Sharman, Juliana M L Biondo, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2021
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and BendamustineAlexey V Danilov, Habte A Yimer, Michael A Boxer, et al.
Blood|October 17, 2015
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemiaJohn C Byrd, Joseph M Flynn, Thomas J Kipps, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Journal of Cell Science|August 6, 2009
Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actinGreg P Coffey, Ranjani Rajapaksa, Raymond Liu, et al.
British Journal of Haematology|September 6, 2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphomaDavid J Andorsky, Kathryn S Kolibaba, Sarit Assouline, et al.
Blood|September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Blood Advances|March 31, 2022
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphomaAnas Younes, John M Burke, Catherine Diefenbach, et al.
BMC Cancer|March 18, 2017
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United StatesChadi Nabhan, Anthony Mato, Christopher R Flowers, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Haematologica|December 17, 2020
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO studyAnthony R Mato, Jeff P Sharman, Juliana M L Biondo, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2021
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and BendamustineAlexey V Danilov, Habte A Yimer, Michael A Boxer, et al.
Blood|October 17, 2015
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemiaJohn C Byrd, Joseph M Flynn, Thomas J Kipps, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Journal of Cell Science|August 6, 2009
Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actinGreg P Coffey, Ranjani Rajapaksa, Raymond Liu, et al.
British Journal of Haematology|September 6, 2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphomaDavid J Andorsky, Kathryn S Kolibaba, Sarit Assouline, et al.
Blood|September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Blood Advances|March 31, 2022
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphomaAnas Younes, John M Burke, Catherine Diefenbach, et al.
BMC Cancer|March 18, 2017
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United StatesChadi Nabhan, Anthony Mato, Christopher R Flowers, et al.
Pageof 8